Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study may spare some breast cancer patients from chemo

NCT ID NCT07423611

First seen Feb 21, 2026 · Last updated Apr 29, 2026 · Updated 8 times

Summary

This study looks at whether a combination of ribociclib and hormone therapy can replace chemotherapy for certain people with early-stage HR+/HER2- breast cancer. About 388 women will be randomly assigned to get either the drug combo alone or chemo first, then the combo. The goal is to see if the combo alone keeps cancer from coming back just as well, using a blood test (ctDNA) to guide treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.